Pipeline

ViGeneron’s pipeline in gene therapy addresses ophthalmic diseases with high unmet medical need, including two lead programs in development for inherited retinal diseases where no approved treatment options are currently available.

For more information about the indications we are working on and the therapies our products offer, please click on the individual indication.

Product
Indication
Gene of interest
Vector
Discovery
In vitro
PoC
Animal
PoC
IND
enabling
Phase
I/II
VG901
Retinitis Pigmentosa
(RP)
>> more
undisclosed small gene
vgAAV
VG801
Inherited Retinal Diseases (IRD)
>> more
undisclosed large gene
vgAAV
Discovery
Age-related Macular Degeneration (AMD)
>> more
novel target
vgAAV